本帖最后由 老马 于 2013-3-13 13:43 编辑
/ l$ V, Z# ~0 N; V/ [
7 z4 d' N2 K1 e健择（吉西他滨）+顺铂+阿瓦斯汀" v) ?) N' Q5 o. i% V5 G* v
Gemzar +Cisplatin + Avastin
) k( X+ F; P7 R& A- n5 [http://annonc.oxfordjournals.org/content/21/9/1804.full7 p1 R- [* g7 ?+ F
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) ( W% V# `- z: a: G' H
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 2 K. j1 E0 E, @$ F) \
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ( Z# c% A$ p* N b8 l ~3 ]' W
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1034)
4 Z2 k, k- ?! T% p3 F1 i
华为网盘附件：
: m9 Q* n3 C+ b `1 O9 X4 c【华为网盘】ava.JPG
! |$ G+ _6 ]: A2 k$ r |
显身卡
